Figure 3. Patients with male gender, KPS>80 points, LDH≤216.
5U/L, limited disease and metastatic sites<2 can benefit more from the treatment of thoracic irradiation (p<0.05 on uni- and multivariate analysis). MST, median survival time.
5U/L, limited disease and metastatic sites<2 can benefit more from the treatment of thoracic irradiation (p<0.05 on uni- and multivariate analysis). MST, median survival time.